Salvage Radiotherapy to the Prostatic Fossa Using Volumetric-modulated Arc Therapy: Early Results

Autor: KK Yuen, Cmm Lui, S.Y. Tung, Fcs Wong, WH Mui, Gml Law, Ekc Lee, Mkh Chan

Publikováno v: Hong Kong Journal of Radiology. 16:191-197

Objectives: Volumetric-modulated arc therapy (VMAT) is better than intensity-modulated radiotherapy (IMRT) in terms of its plan qualities and efficiency for the treatment of prostate cancer. It remains unclear whether its use in salvage radiotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0a76795415a4f3b5efa9855d919d7cb7
https://doi.org/10.12809/hkjr1313173

Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.

Autor: Chiu PKF; S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China., Lee EKC; Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong SAR, China., Chan MTY; Division of Urology, Department of Surgery, Tuen Mun Hospital, Hong Kong SAR, China., Chan WHC; Division of Urology, Department of Surgery, United Christian Hospital, Hong Kong SAR, China., Cheung MH; Division of Urology, Department of Surgery, Tseung Kwan O Hospital, Hong Kong SAR, China., Lam MHC; Department of Oncology, United Christian Hospital, Hong Kong SAR, China., Ma ESK; Department of Pathology, Hong Kong Sanatorium and Hospital, Hong Kong SAR, China., Poon DMC; Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong SAR, China.; Comprehensive Oncology Centre, Hong Kong Sanatorium and Hospital, Hong Kong SAR, China.

Publikováno v: Frontiers in oncology [Front Oncol] 2022 Jul 18; Vol. 12, pp. 962958. Date of Electronic Publication: 2022 Jul 18 (Print Publication: 2022).

A Territory-wide, Multicenter, Age- and Prostate-specific Antigen-matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone-sensitive Prostate Cancer.

Autor: Teoh JYC; S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China., Poon DMC; Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China. Electronic address: mc_poon@clo.cuhk.edu.hk., Lam D; Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China., Chan T; Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China., Chan MFT; Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, China., Lee EKC; Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China., Law S; Department of Oncology, Princess Margaret Hospital, Hong Kong, China., Chan K; Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China., Cheng NM; S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China., Lai KM; S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China., Leung CH; S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China., Ng CF; S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.

Publikováno v: Clinical genitourinary cancer [Clin Genitourin Cancer] 2019 Feb; Vol. 17 (1), pp. e203-e208. Date of Electronic Publication: 2018 Oct 27.

Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone-naïve prostate cancer: The first real-life experience in Asia.

Autor: Poon DMC; Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong., Chan T; Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong., Chan K; Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong., Chan M; Department of Clinical Oncology, Queen Mary Hospital, Pok Fu Lam, Hong Kong., Lee EKC; Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, Hong Kong., Law K; Department of Oncology, Princess Margaret Hospital, Kwai Chung, Hong Kong., Lam D; Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong.

Publikováno v: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2018 Aug; Vol. 14 (4), pp. 347-352. Date of Electronic Publication: 2018 Apr 16.